Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant


Proof of concept, open-label single center study for the donation of HCV positive kidneys to HCV negative patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.

Study Start Date

February, 01 2017

Estimated Completion Date

December 2020


  • Drug: grazoprevir plus elbasvir (fixed dose combination)

Study ID

Massachusetts General Hospital -- 2016P002051



Trial ID


Study Type


Trial Phase

Phase 4

Enrollment Quota



Massachusetts General Hospital

Inclusion Criteria

    1. Must meet MGH transplant center criteria and already be listed for isolated kidney transplant 2. No available living kidney donor 3. Patient has ? 548 days of accrued transplant waiting time 4. Patient on chronic hemodialysis or peritoneal dialysis 5. Weight ? 50kg 6. Serum ALT within normal limits

Exclusion Criteria

    1. AB blood type 2. BMI > 30 3. History of liver disease 4. Pregnant or nursing (lactating) women 5. Cardiomyopathy or pulmonary hypertension 6. Positive crossmatch or positive donor specific antibodies 7. HIV positive 8. HCV RNA positive 9. HBV surface antigen positive 10. Any contraindication to kidney transplant per MGH center protocol




18 Years to 65 Years

Accepts Healthy Volunteers


Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Massachusetts General Hospital - Boston, Massachusetts 2.8 miles Donald Chute BA None provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.